FDA approves infigratinib for previously-treated locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement
Infigratinib is an oral ATP-competitive, tyrosine kinase inhibitor of FGFR. Approval following fast track designation was based on results from a Phase II trial of 108 patients showing an objective response rate of 23% and a duration of response of 5.0 months.
Source:
Biospace Inc.